Shattuck Labs

NEWS

Hand holding pencil erasing an employee. Dismissal or bankrumptcy concept. Vector illustration.

Layoffs

Shattuck Labs to Lay Off 40% of Workforce

As it shifts focus to a death receptor 3 (DR3) antagonist antibody, Shattuck Labs is cutting a significant number of employees before the end of the year.

October 1, 2024

2 min read

Angela Gabriel

Deals

4 Biotech IPOs this Week: Kronos, Shattuck, Spruce and Aziyo

It’s been a fairly busy week for biotech initial public offerings (IPOs) with four announcing their list pricing. Here’s a look.

October 9, 2020

4 min read

Mark Terry

JOBS

IN THE PRESS

Press Releases

Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

October 1, 2024

9 min read

Business

Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights

August 1, 2024

10 min read

Press Releases

Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference

July 31, 2024

1 min read

Drug Development

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) & TP53 mutant AML Patients

June 14, 2024

11 min read

Bio NC

Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)

June 10, 2024

5 min read

Bio NC

Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress

June 6, 2024

5 min read

Drug Development

Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) AML Patients at the EHA 2024 Congress

May 14, 2024

7 min read

Business

Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 2, 2024

11 min read

Drug Development

Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024

April 9, 2024

5 min read

Bio NC

Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference

April 1, 2024

1 min read